Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVIrus Disease 2019

Frontiers in Physiology

Teresa Soda¹  Angelica Perna²  Germano Guerra²  Pawan Faris³  Francesco Moccia³  Sharon Negri³  Roberto Berra-Romani⁴  Antonio De Luca⁵ 

[1] Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy;Department of Medicine and Health Sciences “V. Tiberio”, University of Molise, Campobasso, Italy;Laboratory of General Physiology, Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, Italy;School of Medicine, Department of Biomedicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;Section of Human Anatomy, Department of Mental and Physical Health and Preventive Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy;

关键词: SARS-CoV-2;    COVID-19;    cardiovascular system;    two-pore channels;    PI(3;    5)P2;   

DOI  :  10.3389/fphys.2021.629119

来源: DOAJ

【 摘 要 】

Emerging evidence hints in favor of a life-threatening link between severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and the cardiovascular system. SARS-CoV-2 may result in dramatic cardiovascular complications, whereas the severity of COronaVIrus Disease 2019 (COVID-19) and the incidence of fatalities tend to increase in patients with pre-existing cardiovascular complications. SARS-CoV-2 is internalized into the host cells by endocytosis and may then escape the endolysosomal system via endosomes. Two-pore channels drive endolysosomal trafficking through the release of endolysosomal Ca2+. Recent evidence suggested that the pharmacological inhibition of TPCs prevents Ebola virus and Middle East Respiratory Syndrome COronaVirus (MERS-CoV) entry into host cells. In this perspective, we briefly summarize the biophysical and pharmacological features of TPCs, illustrate their emerging role in the cardiovascular system, and finally present them as a reliable target to treat cardiovascular complications in COVID-19 patients.

【 授权许可】

Unknown